Concepedia

Empagliflozin Administration Can Decrease the Dose of Loop Diuretics and Prevent the Exacerbation of Renal Tubular Injury in Patients With Compensated Heart Failure Complicated by Diabetes

Akihiro Shirakabe, M. Matsushita, Kazutaka Kiuchi, Hirotake Okazaki, Toru Inami, Tsutomu Takayasu, Miwako Asano, Akiko Nomura, Nobuaki Kobayashi, Fumitaka Okajima,

Circulation Reports · 2020 · 20 citations · 20 references

DOIFull text

Open access

Concepts

Abstract

Empagliflozin administration decreased the dose of loop diuretics and increased the production of erythropoietin, which may help prevent renal tubular injury in diabetic outpatients with HF.

References

20

Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.

John G.F. Cleland, Andrew J.S. Coats, Ewa A. Jankowska et al. · PubMed · 2021 · 19.5K citations

, , +12

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

, , +15

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text

, , +17

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Piotr Ponikowski, Adriaan A. Voors, Stefan D. Anker et al. · European Journal of Heart Failure · 2016 · 5.9K citations · Full text

, , +16

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine · 2016 · 3.6K citations · Full text

, , +17